Cargando…

Correction: The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia

Detalles Bibliográficos
Autores principales:	Moharram, Sausan A., Shah, Kinjal, Khanum, Fatima, Rönnstrand, Lars, Kazi, Julhash U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658549/ https://www.ncbi.nlm.nih.gov/pubmed/31346159 http://dx.doi.org/10.1038/s41408-019-0214-8

Ejemplares similares

The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

T-cell Acute Lymphoblastic Leukemia Cells Display Activation of Different Survival Pathways
por: Moharram, Sausan A., et al.
Publicado: (2017)

Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression
por: Shah, Kinjal, et al.
Publicado: (2018)

SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation
por: Rupar, Kaja, et al.
Publicado: (2018)

ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling
por: Kazi, Julhash U., et al.
Publicado: (2017)

Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation
por: Chougule, Rohit A., et al.
Publicado: (2019)

Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis
por: Wang, Yongfeng, et al.
Publicado: (2016)

FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia
por: Chougule, Rohit A., et al.
Publicado: (2016)

Expression of GADS enhances FLT3-induced mitogenic signaling
por: Chougule, Rohit A., et al.
Publicado: (2016)

Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling
por: Moharram, Sausan A., et al.
Publicado: (2016)

Src-Like Adaptor Protein (SLAP) Binds to the Receptor Tyrosine Kinase Flt3 and Modulates Receptor Stability and Downstream Signaling
por: Kazi, Julhash U., et al.
Publicado: (2012)

The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia
por: Shah, Kinjal, et al.
Publicado: (2021)

Combination of AZD3463 and DZNep Prevents Bone Metastasis of Breast Cancer by Suppressing Akt Signaling
por: He, Wenxin, et al.
Publicado: (2021)

BEX1 acts as a tumor suppressor in acute myeloid leukemia
por: Lindblad, Oscar, et al.
Publicado: (2015)

Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD
por: Kazi, Julhash U., et al.
Publicado: (2017)

The Src family kinase LCK cooperates with oncogenic FLT3/ITD in cellular transformation
por: Marhäll, Alissa, et al.
Publicado: (2017)

A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia
por: Nasimian, Ahmad, et al.
Publicado: (2023)

Phosphorylation-Dependent Regulation of WNT/Beta-Catenin Signaling
por: Shah, Kinjal, et al.
Publicado: (2022)

Understanding the Role of Activation Loop Mutants in Drug Efficacy for FLT3-ITD
por: Kazi, Julhash U., et al.
Publicado: (2023)

AZD3463, an IGF-1R inhibitor, suppresses breast cancer metastasis to bone via modulation of the PI3K-Akt pathway
por: Hu, Guang-Fu, et al.
Publicado: (2020)

T cell receptor (TCR) signaling in health and disease
por: Shah, Kinjal, et al.
Publicado: (2021)

3463 Frontal Alpha Asymmetry in Alcohol-Related Intimate Partner Violence
por: Fink, Brandi C
Publicado: (2019)

P479: TREATMENT IS SHAPING CLONAL EVOLUTION AND RESISTANCE PATTERNS IN MURINE KMT2A-REARRANGED LEUKEMIA WITH SUBCLONAL FLT3N676K
por: Falqués-Costa, Ton, et al.
Publicado: (2023)

Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine Signaling
por: Shah, Kinjal, et al.
Publicado: (2023)

Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
por: Halbach, Sebastian, et al.
Publicado: (2016)

Mycobacterium tuberculosis Rv3463 induces mycobactericidal activity in macrophages by enhancing phagolysosomal fusion and exhibits therapeutic potential
por: Park, Hye-Soo, et al.
Publicado: (2019)

Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib
por: Macias, Rocio I.R., et al.
Publicado: (2018)

Mechanisms of Anticancer Therapy Resistance: The Role of Cancer Stem Cells
por: Kazi, Julhash U.
Publicado: (2020)

PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia
por: Shah, Kinjal, et al.
Publicado: (2023)

Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480
por: Gudernova, Iva, et al.
Publicado: (2017)

HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2016)

The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression
por: Harada, Masako, et al.
Publicado: (2015)

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
por: Tron, Adriana E., et al.
Publicado: (2018)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

Metallopeptidase inhibitor 1 (TIMP‐1) promotes receptor tyrosine kinase c‐Kit signaling in colorectal cancer
por: Nordgaard, Cathrine, et al.
Publicado: (2019)

Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Correction: ALK inhibitors in ALK-rearranged nonsmall cell lung cancer with and without brain metastases: systematic review and network meta-analysis
Publicado: (2022)

Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl‐1 Inhibitor AZD5991
por: Goliaei, Ardeshir, et al.
Publicado: (2020)

Correction: Transcriptome analysis of intestine from alk-SMase knockout mice reveals the effect of alk-SMase
por: Zhu, Jiang, et al.
Publicado: (2022)

Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_85o4tdgcjpfqp3h9dbhkh1dqhb